Supprelin Implant
NDC Package 67979-002-01
Package Information
Supprelin (histrelin acetate) implants is histrelin is used in men to treat advanced prostate cancer. This formulation utilizes a implant delivery system. Marketed by Endo Usa, Inc., this product is identified by NDC 67979-002 and is authorized under FDA application NDA022058.
Identification & Billing
- RxCUI: 1294641 - Supprelin LA 50 MG (65 MCG per 24HR) Subcutaneous Drug Implant
- RxCUI: 1294641 - histrelin acetate 0.00271 MG/HR Drug Implant [Supprelin]
- RxCUI: 1294641 - Supprelin 50 MG (65 MCG per 24 HR) Drug Implant
- RxCUI: 1740437 - histrelin acetate 50 MG (65 MCG per 24HR) Subcutaneous Drug Implant
- RxCUI: 1740437 - histrelin acetate 0.00271 MG/HR Drug Implant
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 67979 - Endo Usa, Inc.
- 67979-002 - Supprelin
- 67979-002-01 - 1 VIAL, GLASS in 1 CARTON / 1 IMPLANT in 1 VIAL, GLASS
- 67979-002 - Supprelin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 67979-002-01 identifies a specific commercial package of 1 vial, glass in 1 carton / 1 implant in 1 vial, glass of Supprelin LA, a human prescription drug labeled by Endo Usa, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This implant is formulated for subcutaneous use and contains histrelin acetate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Endo Usa, Inc. on May 31, 2007. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Histrelin is used in men to treat advanced prostate cancer. It is not a cure. Most types of prostate cancer need the male hormone testosterone to grow and spread. Histrelin works by reducing the amount of testosterone that the body makes. This helps slow or stop the growth of cancer cells and helps relieve symptoms such as painful/difficult urination. Talk to your doctor about the risks and benefits of treatment. Histrelin is also used in children to treat early puberty (central precocious puberty). It helps to slow abnormally fast bone development so that height and growth rate are near normal and to stop or reverse signs of early puberty (such as breast/pubic hair growth in girls, pubic hair growth in boys). Histrelin works by reducing the amount of testosterone in boys and estrogen in girls. This medication is used until the doctor decides it is time for puberty to resume.
How is this Endo Usa, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 67979000201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.